ArticleMolecular medicine reports2026
Protective effects of Notoginsenoside R1 on the ferroptosis of a human non‑small cell lung cancer cell line.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigated the effects of Notoginsenoside R1 (NG‑R1) on human non‑small cell lung cancer (NSCLC) A549 cells and explored its potential mechanisms. Cell viability was assessed using the MTT assay after 72 h of treatment with varying concentrations of NG‑R1 (0.1, 0.2, 0.4, 0.8, 1.6 and 2 mg/ml), which inhibited A549 cell viability in a dose‑dependent manner. Cell proliferation, migration and invasion were evaluated using the BeyoClick™ EdU‑594 proliferation assay, wound healing assay and Matrigel®‑coated Transwell invasion assay, respectively. NG‑R1 at concentrations of 0.4, 0.8 and 1.6 mg/ml significantly suppressed proliferation, migration and invasion of A549 cells compared with the control. In addition, these doses of NG‑R1 increased intracellular reactive oxygen species (ROS) levels as measured using the fluorescent probe 2',7'‑dichlorofluorescein diacetate. Western blot analysis revealed that treatment with NG‑R1 (0.4, 0.8 and 1.6 mg/ml) upregulated the expression of the ferroptosis‑related protein transferrin receptor 1, and downregulated solute carrier family 7 member 11, glutathione peroxidase 4 and ferritin heavy chain 1. Collectively, these findings indicate that NG‑R1 inhibited the proliferation of NSCLC A549 cells, likely through the induction of ROS accumulation and ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.